Researchers at the Bonn University Department of Ophthalmology and US colleagues successfully implanted new cells under the retina
Age-related macular degeneration (AMD) is the most frequent cause of blindness. Scientists at the Department of Ophthalmology at the Bonn University Hospital and from the Neural Stem Cell Institute in New York (USA) have developed a method for using stem cells to replace cells in the eye destroyed by AMD. The implants survived in rabbit eyes for several weeks. Additional research is needed for clinical application. The results are now presented in the journal “Stem Cell Reports”.
About four and a half million people in Germany suffer from age-related macular degeneration (AMD). It is associated with a gradual loss of visual acuity and the ability to read or drive a car can be lost. The center of the field of vision is blurry, as if covered by a veil. This is caused by damage to a cell layer under the retina, known as the retinal pigment epithelium (RPE). It coordinates the metabolism and function of the sensory cells in the eye. Inflammatory processes in this layer are associated with AMD and “metabolic waste” is less efficiently recycled. To date, there is no cure for AMD; treatments can only relieve the symptoms.
Scientists from the Bonn University Department of Ophthalmology, together with researchers in New York (USA), have now tested a new method in rabbits by which the damaged RPE cells in AMD may be replaced. The researchers implanted different RPEs which were obtained, among others, from stem cells from adult human donors. “These cells have now been used for the first time in research for transplantation purposes,” says lead author Dr. Boris V. Stanzel from the Department of Ophthalmology at the University of Bonn. The discovery and characterization of the adult RPE stem cells was performed in the group of Prof. Sally Temple and Dr. Jeffrey Stern from the Neural Stem Cell Institute (NSCI) in New York, USA. Dr. Timothy Blenkinsop at NSCI pioneered methods to grow them to closely resemble true RPE.
Researchers in Bonn developed the implantation techniques
The implantation techniques for the new method were developed by researchers working with Dr. Stanzel from the Department of Ophthalmology at the University of Bonn. They allowed the stem cell derived RPE to grow on small polyester discs, thus yielding a thin cell layer. The researchers implanted this human RPE monolayer in rabbits under the retina. “Our research group developed special instruments to implant the replacement cells can under the retina,” reports Dr. Stanzel. After four days, the researchers used tomographic methods to check whether the replacement cells had integrated into the surrounding cell layers. “The implanted cells were alive,” reports the researcher at the Department of Ophthalmology at the University of Bonn. “That is a clear indication that they have joined with the surrounding cells.” After one week, the implanted cell layer was still stable. Even after four weeks, tissue examinations showed that the transplant was intact.
A new approach for possible treatment of AMD
“The results from the experiments prove that retinal pigment epithelial cells obtained from adult stem cells have the potential to replace cells destroyed by age-related macular degeneration,” summarizes Dr. Stanzel. Moreover, using the newly developed basic method, it will be possible in the future to test which stem cell lines are suitable for transplantation in the eye. “However, clinical application is still far away,” says Dr. Stanzel. More research is needed.
The Latest on: Macular degeneration
via Google News
The Latest on: Macular degeneration
- Adverum Biotechnologies reports positive interim data from three cohorts of OPTIC phase 1 trialon May 13, 2020 at 6:48 am
New interim data for the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy for the treatment of wet age-related macular degeneration showed robust efficacy in ...
- The hidden struggles America's disabled are facing during the coronavirus pandemicon May 12, 2020 at 2:16 pm
Millions of Americans who suffer from hearing and vision loss claim measures for the disabled, with regard to public health emergency response planning, have been less than adequate in the Covid-19 ...
- Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Densityon May 12, 2020 at 4:10 am
First study to provide a head-to-head comparison of two commercially available supplements with regard to the changes in serum levels of ...
- Global Macular Degeneration Drugs Market 2020 Analysis, Top Manufacturers, Market Size, Share, Growth Factor and Forecast to 2025on May 12, 2020 at 4:04 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Macular Degeneration Drugs ...
- Global Age-Related Macular Degeneration Market and Competitive Landscape 2020 - ResearchAndMarkets.comon May 12, 2020 at 1:35 am
This research report provides comprehensive insights into the Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares ...
- Anti-VEGF-resistant subretinal fluid may lead to decreased risk for macular atrophyon May 8, 2020 at 2:38 pm
VEGF treatment may operate as a compensatory mechanism that maintains the function of the degenerating macula and prevents progression to atrophy, according to one presenter at the virtual Association ...
- Global Pipeline Drug Forecasts for Age-Related Macular Degeneration - ResearchAndMarkets.comon May 8, 2020 at 2:00 am
Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration of the macula, which is the oval-shaped area of the retina that is responsible for central ...
- Insights into the Macular Degeneration Treatment Market to 2025 - Growth, Trends and Forecaston May 6, 2020 at 7:45 am
The "Macular Degeneration Treatment Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The macular degeneration treatment market was ...
- Potential New Drug Target for Age-Related Macular Degenerationon May 6, 2020 at 5:00 am
Scientists have identified an unexpected player in the immune reaction gone awry that is involved in age-related macular degeneration.
- Study finds unexpected suspect in age-related macular degenerationon May 5, 2020 at 9:32 am
Scientists have identified an unexpected player in the immune reaction gone awry that causes vision loss in patients with age-related macular degeneration (AMD), according to a new study published ...
via Bing News